The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation.

abstract：:The plasma pharmacokinetics of the anti-tumor antibiotic geldanamycin (GM: NSC 122750), a naturally occurring benzoquinoid ansamycin, was characterized in mice and a beagle dog. Concentrations of GM well above 0.1 microgram/ml, which was typically effective against neoplastic cell lines responsive to the drug in vitro...

journal_title：Cancer chemotherapy and pharmacology

authors： Supko JG,Hickman RL,Grever MR,Malspeis L

更新日期：1995-01-01 00:00:00

abstract：:The development of more effective treatment strategies currently provides the only realistic hope of reducing breast cancer mortality. Among such treatments, high-dose chemotherapy (HDC) has been proposed to be a potentially curative strategy. Consideration of the factors involved in the successful treatment of human ...

journal_title：Cancer chemotherapy and pharmacology

authors： Bezwoda WR

更新日期：1997-01-01 00:00:00

abstract：:The cytotoxicity of cisplatin alone and in combination with topotecan (TPT) or SN-38, two novel topoisomerase I (topo I) inhibitors, was determined in a panel of eight well-characterized human solid-tumor cell lines. Interactions between cisplatin and these topo I inhibitors were investigated using three different adm...

journal_title：Cancer chemotherapy and pharmacology

authors： Ma J,Maliepaard M,Nooter K,Boersma AW,Verweij J,Stoter G,Schellens JH

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:The ERCC1-XPF 5'-3' DNA endonuclease complex is involved in the nucleotide excision repair pathway and in the DNA inter-strand crosslink repair pathway, two key mechanisms modulating the activity of chemotherapeutic alkylating agents in cancer cells. Inhibitors of the interaction between ERCC1 and XPF can be us...

journal_title：Cancer chemotherapy and pharmacology

authors： Ciniero G,Elmenoufy AH,Gentile F,Weinfeld M,Deriu MA,West FG,Tuszynski JA,Dumontet C,Cros-Perrial E,Jordheim LP

更新日期：2021-01-05 00:00:00

abstract：PURPOSE:Epigenetic silencing of tumor suppressor genes (TSGs) by aberrant DNA methylation and chromatin deacetylation provides interesting targets for chemotherapeutic intervention by inhibitors of these events. 5-Aza-2'-deoxycytidine (decitabine, 5AZA-CdR) is a potent demethylating agent, which can reactivate TSGs sil...

journal_title：Cancer chemotherapy and pharmacology

authors： Hurtubise A,Momparler RL

更新日期：2006-11-01 00:00:00

abstract：PURPOSE:SU5416 is a novel small organic molecule that non-competitively inhibits the phosphorylation of the VEGF tyrosine kinase receptor, Flk-1. This phase IB study was performed to determine the safety, pharmacokinetics, and preliminary efficacy of the combination of SU5416 and paclitaxel in recurrent or metastatic c...

journal_title：Cancer chemotherapy and pharmacology

authors： Cooney MM,Tserng KY,Makar V,McPeak RJ,Ingalls ST,Dowlati A,Overmoyer B,McCrae K,Ksenich P,Lavertu P,Ivy P,Hoppel CL,Remick S

更新日期：2005-03-01 00:00:00

abstract：:Trastuzumab has deeply and radically changed the course of HER2-positive breast cancer disease. The recent development of a subcutaneous (SC) formulation of trastuzumab is an important step towards improved patients' care. SC trastuzumab at a fixed dose of 600 mg administered every 3 weeks for about 5 min provides a v...

journal_title：Cancer chemotherapy and pharmacology

authors： Launay-Vacher V

更新日期：2013-12-01 00:00:00

abstract：PURPOSE:Malignant rhabdoid tumors (MRT), although rare, are one of the most aggressive pediatric malignancies. Loss of INI1, a tumor suppressor gene and member of the SWI/SNF chromatin remodeling complex, is a recurrent genetic characteristic of these tumors and an important diagnostic marker. We have previously demons...

journal_title：Cancer chemotherapy and pharmacology

authors： Foster K,Wang Y,Zhou D,Wright C

更新日期：2009-04-01 00:00:00

abstract：:CI-958, a new DNA-intercalating drug derived from a series of substituted 2H-[1] benzothiopyrano[4,3,2-cd]indazoles, is being tested in clinical trails because of its curative properties against murine solid tumor models and because it has demonstrated activity in a pilot phase II study of patients with hormone-refrac...

journal_title：Cancer chemotherapy and pharmacology

authors： Lun L,Sun PM,Trubey CM,Bachur NR

更新日期：1998-01-01 00:00:00

abstract：:The cellular metabolism of 3'-amino-2',3'-dideoxycytidine (3'-NH2-dCyd), a cytotoxic agent previously reported to be a poor substrate for purified Cyd/dCyd deaminase (dCydD), was compared with that of cytosine arabinoside (ara-C) in cells that displayed dCydD activity (HeLa) and in cells that did not (L1210). Growth i...

journal_title：Cancer chemotherapy and pharmacology

authors： Mancini WR

更新日期：1992-01-01 00:00:00

abstract：:The pharmacokinetics of mitomycin (MMC) was studied in Wistar rats. Up to five half-lives, the plasma concentration-time curve was biphasic. The AUC changed linearly with increasing doses between 0.5 and 7.5 mg/kg, which corresponds to 0.2 and 3 times the LD50 value in rats. Most of the drug was metabolized, and only ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kerpel-Fronius S,Verwey J,Stuurman M,Kanyár B,Lelieveld P,Pinedo HM

更新日期：1988-01-01 00:00:00

abstract：PURPOSE:Predictors of response or disease control with oral medroxyprogesterone acetate (MPA) therapy in patients with metastatic or recurrence endometrial cancer remain to be elucidated. The purpose of this study was to clarify the effect of MPA in patients with endometrial cancer and identify markers that predict MPA...

journal_title：Cancer chemotherapy and pharmacology

authors： Yunokawa M,Yoshida H,Watanabe R,Noguchi E,Shimomura A,Shimoi T,Yonemori K,Shimizu C,Fujiwara Y,Tamura K

更新日期：2017-07-01 00:00:00

abstract：:The primary development of clinical resistance to 1-beta-D-arabinofuranosyl cytosine (ara-C) in leukemic blast cells is expressed as decreased cellular concentrations of its active anabolite. Correlations exist between the cellular concentrations of 1-beta-D-arabinofuranosyl cytosine 5'-triphosphate (ara-CTP) in leuke...

journal_title：Cancer chemotherapy and pharmacology

authors： Avramis VI,Mecum RA,Nyce J,Steele DA,Holcenberg JS

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:Second-line chemotherapy in patients with metastatic gastric cancer (MGC) pre-treated with cisplatin is not a standard option. We studied a combination of irinotecan, fluorouracil and folates. METHODS:Patients progressive to cisplatin-based chemotherapy were enrolled. Irinotecan 180 mg/m(2), folinic acid 200 m...

journal_title：Cancer chemotherapy and pharmacology

authors： Lorizzo K,Fazio N,Radice D,Boselli S,Ariu L,Zampino MG,Nolè F,Magni E,Ardito R,Minchella I,Rocca A,Di Meglio G,Squadroni M,de Braud F

更新日期：2009-07-01 00:00:00

abstract：PURPOSE:To review the 20 years of experience at M. D. Anderson Cancer Center with a combined-modality approach against inflammatory breast carcinoma. PATIENTS AND METHODS:A total of 178 patients with inflammatory breast carcinoma were treated in the past 20 years at M. D. Anderson Cancer Center by a combined-modality ...

journal_title：Cancer chemotherapy and pharmacology

authors： Ueno NT,Buzdar AU,Singletary SE,Ames FC,McNeese MD,Holmes FA,Theriault RL,Strom EA,Wasaff BJ,Asmar L,Frye D,Hortobagyi GN

更新日期：1997-01-01 00:00:00

abstract：PURPOSE:The intra-tumour distribution of anticancer drugs remains an important, but often under-estimated, influence on drug efficacy. Tumour acidity and the presence of efflux pumps were examined for their influence on the distribution of doxorubicin in a solid tumour model. METHODS:Anticancer drug distribution and o...

journal_title：Cancer chemotherapy and pharmacology

authors： Mellor HR,Callaghan R

更新日期：2011-11-01 00:00:00

abstract：PURPOSE:The purpose of this study was to evaluate the expression of ser-miRNAs at different periods during treatment and analyze their relationship with therapeutic response and prognosis in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab (NCCT). METHODS:Venous blood w...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu B,Su F,Lv X,Zhang W,Shang X,Zhang Y,Zhang J

更新日期：2019-11-01 00:00:00

abstract：:Flavone acetic acid (FAA, NSC 347512) is a synthetic flavonoid compound with a unique form of preclinical antitumor activity, but its mechanism of action is still not known. In an attempt to exploit the remarkable preclinical activity of this compound in such a way as to allow its use as a clinically useful agent, we ...

journal_title：Cancer chemotherapy and pharmacology

authors： de Forni M,Chabot GG,Armand JP,Gouyette A,Klink-Alak M,Recondo G

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:Angiotensin (1-7) [A(1-7)] is a bioactive peptide of the renin angiotensin system that stimulates the number of bone marrow progenitors and hematopoietic recovery after myelosuppression. We evaluated the combination of A(1-7) with colony-stimulating factors, Neupogen and Epogen, on bone marrow progenitors and t...

journal_title：Cancer chemotherapy and pharmacology

authors： Rodgers KE,Espinoza TB,Roda N,Meeks CJ,diZerega GS

更新日期：2013-12-01 00:00:00

abstract：:We reviewed 139 resected patients with hepatocellular carcinoma at our clinic between 1963 and 1987, and using the 118 cases for the period between 1963 and 1986, we analyzed the prognostic factors that influenced the long-term prognosis by comparing the survival curves. Significant differences in the survival pattern...

journal_title：Cancer chemotherapy and pharmacology

authors： Kawano N,Ohmori Y,Inoue S,Nagao T,Morioka Y

更新日期：1989-01-01 00:00:00

abstract：:Lung cancer is the leading cause of cancer death in the world. Recently, targeted therapy and anti-programmed cell death receptor 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) immunotherapy have made great progress in treatment of lung cancer. However, responses to these therapies are variable, influenced b...

journal_title：Cancer chemotherapy and pharmacology

authors： Huang C,Liu S,Tong X,Fan H

更新日期：2018-08-01 00:00:00

abstract：PURPOSE:Paclitaxel-based chemoradiotherapy was proven to be efficacious in treating patients with advanced esophageal cancer. However, the toxicity and the development of resistance limited its anticancer efficiency. The present study was to evaluate the antitumor effects of lapatinib, a dual tyrosine inhibitor of both...

journal_title：Cancer chemotherapy and pharmacology

authors： Guo XF,Li SS,Zhu XF,Dou QH,Liu D

更新日期：2018-09-01 00:00:00

abstract：PURPOSE:Mutations and activations of the MEK and PI3K pathways are associated with the development of many cancers. GDC-0973 and GDC-0941 are inhibitors of MEK and PI3K, respectively, currently being evaluated clinically in combination as anti-cancer treatment. The objective of these studies was to characterize the rel...

journal_title：Cancer chemotherapy and pharmacology

authors： Choo EF,Ng CM,Berry L,Belvin M,Lewin-Koh N,Merchant M,Salphati L

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Cetuximab and panitumumab are chimeric and fully human monoclonal antibodies, respectively, against epidermal growth factor receptor used in the treatment of metastatic colorectal cancer (mCRC). Incidence of documented infusion reaction (IR) is more common with cetuximab (all grades [g]: 15-21%, g 3/4: 2-5%)...

journal_title：Cancer chemotherapy and pharmacology

authors： Saif MW,Syrigos KI,Hotchkiss S,Shanley J,Grasso J,Ferencz TM,Syrigos K,Shah MM

更新日期：2009-12-01 00:00:00

abstract：:Tumor angiogenesis is essential for tumor growth and metastasis formation. Luminex methodology was used to measure the levels of four angiogenic cytokines in cell culture medium and in the plasma of mice bearing human tumors. We obtained plasma and conditioned culture medium from 12 different human tumor cell lines. T...

journal_title：Cancer chemotherapy and pharmacology

authors： Keyes KA,Mann L,Cox K,Treadway P,Iversen P,Chen YF,Teicher BA

更新日期：2003-04-01 00:00:00

abstract：PURPOSE:The present study was designed to investigate the ability of N-[4-(5-bromo-2-pyrimidyloxy)-3-methylphenyl]-(dimemethylamino)-benzoylphenylurea (dimemethylamino benzoylphenylurea; BPU) to sensitize cells to radiation and to examine the relationship between phenotype versus survival, DNA damage, apoptosis, or cel...

journal_title：Cancer chemotherapy and pharmacology

authors： Balcer-Kubiczek EK,Attarpour M,Edelman MJ

更新日期：2007-05-01 00:00:00

abstract：:3-Deazaguanine (3-DG), a purine analogue, has unusual antitumor activity against experimental mammary tumor models and a number of other solid tumors. Others have shown that mutant CHO cells deficient in hypoxanthine guanine phosphoribosyl transferase (HGPRTase) or adenine phosphoribosyl transferase (APRTase) are resi...

journal_title：Cancer chemotherapy and pharmacology

authors： Singh G,Luna MK,Ardalan B

更新日期：1988-01-01 00:00:00

abstract：:RS-1541, an acyl-derivative of rhizoxin (Fig. 1), is a potent antitumor compound. This agent showed cytotoxicity in vitro on some cultured human tumor cells, although it was less potent than rhizoxin. Rhizoxin exhibited antitumor effects by inhibiting the polymerization of tubulin, whereas RS-1541 did not inhibit tubu...

journal_title：Cancer chemotherapy and pharmacology

authors： Takatori T,Koizumi T,Tokui T,Mitsuhashi Y,Shiraishi A,Tsuruo T

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:To explore the clinical significance of plasma D-dimer increase for transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer (PLC). METHODS:The clinical data of 80 PLC patients who underwent TACE in our hospital from January 2015 to January 2017 were collected, including the plasma...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen X,Chang Z,Liu Z

更新日期：2019-04-01 00:00:00

abstract：PURPOSE:Anti-epidermal growth factor receptor antibody therapy alone or in combination with irinotecan is recognized as a standard third-line treatment for KRAS wild-type unresectable metastatic colorectal cancer. However, in some cases, it is difficult to administer irinotecan after third-line treatment. Therefore, we...

journal_title：Cancer chemotherapy and pharmacology

authors： Takahashi T,Emi Y,Oki E,Kobayashi K,Tsuji A,Shimokawa M,Tanaka T,Akagi Y,Ogata Y,Baba H,Yoshida K,Natsugoe S,Maehara Y,Kyushu Study Group of Clinical Cancer (KSCC).

更新日期：2016-09-01 00:00:00